These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 11156242)
1. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242 [TBL] [Abstract][Full Text] [Related]
2. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766 [TBL] [Abstract][Full Text] [Related]
3. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277 [TBL] [Abstract][Full Text] [Related]
4. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017 [TBL] [Abstract][Full Text] [Related]
5. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791 [TBL] [Abstract][Full Text] [Related]
7. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
8. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
9. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240 [TBL] [Abstract][Full Text] [Related]
10. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732 [TBL] [Abstract][Full Text] [Related]
11. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells. Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594 [TBL] [Abstract][Full Text] [Related]
12. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350 [TBL] [Abstract][Full Text] [Related]
13. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620 [TBL] [Abstract][Full Text] [Related]
14. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Lee PP; Yee C; Savage PA; Fong L; Brockstedt D; Weber JS; Johnson D; Swetter S; Thompson J; Greenberg PD; Roederer M; Davis MM Nat Med; 1999 Jun; 5(6):677-85. PubMed ID: 10371507 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996 [TBL] [Abstract][Full Text] [Related]
17. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347 [TBL] [Abstract][Full Text] [Related]
18. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986 [TBL] [Abstract][Full Text] [Related]